Development of evaluation tools for assessing capabilities in health technology by Rogers, Juan
 
Development of Evaluation Tools for Assessing  












Juan D. Rogers 
School of Public Policy 
Georgia Institute of Technology 
685 Cherry Street NW 
Atlanta, GA 30332-0345 
USA 
 
Tel: (404) 894-6697 















In this report we present the fundamentals of a strategy for capacity assessment of 
applicants for public R&D funding in health technology (HT). It is important to have a 
way to assess capacity because proposals for new projects often contain good ideas for 
projects but do not offer a direct way to gauge if the team or organization of the 
proponent is able to sustain the right sort of effort to bring the ideas to fruition.  
 
The report contains a model of health technology projects review and evaluation, a set 
of proposed indicators of health technology development capacity that emerges from 
the model and an outline of data needs for designing the data base to continuously 
monitor capacity as the experience of funding projects continues.  
 
II. Health Technology Project Review and Evaluation Model 
 
Evaluations are most often focused on the realization of the explicit goals of programs 
and policies. The evaluation of HT projects would then mostly involve the congruence 
between the technical features of the proposed technology and the goals of the program 
to which the application for funding is submitted. In addition, the technical merit of the 
project would be assessed to decide an award.  
 
There are alternative implicit objectives of R&D policies that are not always stated as 
goals of the specific programs and policies in question. Given that R&D is involved with 
knowledge and learning, it is generally expected that the results of R&D funding will not 
only be the completion of the content goals of the proposed projects but that the 
researchers, teams and organizations that receive funding will be in a position to do 
future similar projects or take the next steps toward the logical challenges that follow 
with the capacity developed to address the present project. Ordinary R&D performance 
indicators do not capture capacity building very well. The assessment of capacity will 
also provide a more firm basis for setting expectations for future programs because 
information about the population of candidate performance will accumulate if followed in 
time. If capacity assessment is tracked with the technical content of the projects, then a 
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diversified set of candidates will be identified with knowledge of the technical focus of 
their specific strengths. In order to make effective use of capacity assessment in the 
award of projects to develop the HT field, the agency should take an active role 
monitoring the field of potential project performers. This activity will serve as input to the 
design of future programs and potentially give the agency the ability to guide and 
stimulate the evolution of the field.  
 
The strategy we propose in this report has two theoretical components. First, it adopts 
the Scientific and Technical Human Capital (STHC) framework for analysis of 
researchers, teams and organizations involved in R&D (Dietz & Bozeman 2005). 
Second, it proposes a model of HT development that an agency such as KISTEP might 
use to frame the proposals. The STHC is a general framework of scientific and technical 
work that combines information on the technical content of R&D workers from 
publications, grant proposals, contracts, patents, and other such materials with 
information on the networks of interaction used to pursue scientific goals including 
collaborators and contacts in other organizations. The sources of this information are 
publication databases, grant databases, CVs, and possibly direct calls to members of 
the teams for specific items.  
 
The model of HT project review and evaluation reflects the position of KISTEP and its 
potential strategy in technology development within which HT projects would fit. This 
model addresses the institutional and technical context within which KISTEP supports 
HT projects and allows the inference of some background priorities that must be taken 
into consideration when assessing project proposals. It also considers the audiences for 
which the measures of capacity are intended and assumes they are mainly internal to 
the organization for program management and improvement.  
 
The model of HT development highlighting the role of KISTEP consists in the following 
components: 
 
• HT development R&D contexts 
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• Markets for HT 
• KISTEP strategic plan as it relates to HT 
• HT project selection processes 
• HT project monitoring processes  
• KISTEP HT program evaluation 
• HT Technology Opportunities Analysis (TOA) 
• HT Capacity Asessment 
• Data Requirements and Resources 
 
The links between these components are shown in figure 1.  
 
A KISTEP HT program operates in the context of the overall innovation system for these 
technologies. For the purposes of this analysis we only represent two of the 
components of that system that directly interface with the issue at hand, namely, first, 
the set of firms with R&D capabilities in HT and other R&D facilities that may apply for 
project grants in these programs and, second, the markets in which demand for HT is 
projected.  
 
KISTEP will have a strategic plan for HT that is grounded in the priorities given by policy 
but articulated for the case of this field of technology by an empirical analysis of 
technology opportunities in HT (TOA). This analysis will allow for setting specific HT 
targets that will be made explicit in grant competition instructions or whatever instrument 
is used to generate the interest of potential candidates for HT projects.  
 
These priorities and technological focus will guide the substance of the project selection 
process which then leads to the monitoring of awarded projects which in turn leads to 
the ex-post performance evaluation of both executed projects and the program. The 
latter evaluation stage will have an inevitable economic component given that 
technologies are expected to be taken to market, even when the benefits in the case of 
health are not only private rent for commercial firms but also economic effects on the 
healthcare system in terms of changes of cost and menus of offered health services. 
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The details of these economic models of HT performance are the province of ex post 
health technology assessment (HTA) and they exceed the purview of this project 
(Giovagnoni et al. 2009).  
 
In this model, the HT Capacity Assessment (HTCA), which is the focus of this report, is 
a process that is based on the articulation of priorities set in the strategic plan for HT 
and takes information from the subset of eligible HT performing entities to inform the 
project selection process. The TOA will also inform the HTCA in order to fine tune 
capacity indicator design. A data base of information on HT will draw on three sources, 
the results of TOA, HTCA and ongoing evaluation processes. 
 
In this report we develop the HTCA component using the rest of the model as the 
background assumptions for its design. The details of strategic planning, HT project 
selection and performance evaluation are not necessary and may exist in a variety of 
forms at KISTEP. Two modules of this model may already exist, but if they are not, they 
are recommended for implementation by this report. These are, first, a HT Technology 
Opportunities Analysis (TOA) and, second, a HT Project Monitoring process.  
 
There is a general and a particular reason for recommending the implementation of 
these processes. The general reason is the international experience of technology 
focused publicly supported programs. Technology development programs are subject to 
stringent evaluation by policy makers given the expectations that they make a difference 
in the overall competitiveness of countries’ or regions’ innovation systems. Without an 
empirically based analysis of technological opportunities it is very difficult to set 
reasonable priorities for these projects. Furthermore, in the area of health technology 
assessment, which would be a necessary dimension of the performance evaluation of 
an HT program, there is a growing trend toward health technology “horizon scanning” of 
emerging health technologies to set criteria in HTA (O’Malley & Jordan 2009).  
 
In the case of project monitoring, the complexities of technology development programs 
often require interventions during execution to address circumstances that were not 
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anticipated during the proposal review stage. In the United States, both DARPA 
technology projects and those in the now defunct Advanced Technology Projects, owed 
their success to careful monitoring of projects as well as learning from multiple stage 
follow up of the project performers after the project was concluded (Ruegg 1998). As a 
matter of fact, the ATP experience is probably a very relevant one for learning from one 
of the most intensive efforts in publicly funded technology development program 
evaluation (Ruegg & Feller 2003). 
 
The special reason for recommending TOA and HT project monitoring is that they are 
intimately connected to capacity assessment. The indicators of capacity need a clear 
reference to context in order to gain some precision. As we will see below, the very 
nature of a priori capacity assessment makes precision and specificity difficult. This can 
be compensated for by using additional information from the technological horizon as 
determined by the TOA and the demonstrated capacity during the progress of project 
execution.  
 
There is one caveat that must be mentioned. Drug development is possibly completely 
different from other sorts of HT. The generic model described here may not be 
adequate given that drugs are treated as special technologies by regulatory regimes. 
This is highlighted by the fact that there is a separate track of HTA in Korea for drug 
development (Kim 09). There is no attempt in this report to cover the potential 
differences that might make drug development a special case. 
 
 
III. Indicators of Health Technology Development Capacity 
 
a. Some background observations 
The determination of capacity or ability to deliver R&D results at a certain level of 
performance has inherent uncertainties. Capacity assessment is a prediction of future 
performance based on past experiences and performance. The measurement of both 
components is difficult and their predictive value is not always clear. There is also an 
inherent conservatism in the notion that having done similar things before is the best 
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qualification for future projects. It is by design discriminatory against new entrants and 
changes in technological trajectory for which past similarities don’t really exist. Forcing 
the appearance of continuity stifles the proposal of new approaches. Therefore, these 
indicators of capacity must be used with care and in the context of a historical record so 
these weaknesses can be compensated for.  
 
We will assume that the performers of HT projects may be private firms, government 
labs, academic labs or joint ventures of any of the latter with private firms or of more 
than one private firm. Rather than focus on the details of the combinations of actors, 
what we are really aiming for is to avoid limiting the set of performers to the academic or 
public sector and to introduce the possibility of collaborative ventures. The latter have 
special characteristics from the point of view of capacity and also from the expected 
outcomes of projects. Collaboration across sectors or of more than one private firm on 
these projects often leads to a change in the culture of the participating organizations 
that may be a desirable outcome in its own right.  
 
b. Indicator categories and definitions 
 
We propose indicators of capacity in two main category families: the technical 
competence of the technology development team and the organizational context of the 
lab, firm or joint venture. The first set of categories reflects the human and social capital 
embodied in the performers of the technical work in the form of explicit and tacit 
knowledge from formal education and past experience, their past work experience, 
collaborative projects and accomplishments reflected in publications, patents, awards 
and other evidence of past performance.  
 
The second set of categories addresses both the material and organizational 
infrastructure and some of the social capital embedded in some specific organizational 
capabilities such as the participation in prior joint ventures, their commercial and market 
networks and their participation in health regulated processes, which are important for 




Table: Health Technology Capacity Assessment Indicators 
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c. Indicator Interpretation 
The interpretation of these indicators in order to draw conclusions about capacity must 
be done with careful attention to some basic principles. First, the assessed level of 
capacity is not a one dimensional ranking since the activities in technological 
development are multifarious, so are the capacities to do things. Therefore, the 
simplistic interpretations of one time, single indicator hierarchies must be avoided at all 
costs.  
 
In the same vein, second, the procedure should aim for building profiles of firms, labs 
and collaborative organizations at the organizational level and of members of technical 
teams at the individual level. Both of these should be tracked in time. The basis for 
these profiles will function as working hypotheses that are continuously tested and 
updated as data and experience accumulate. As experience with the data and the set of 
performers in the field grows, the critical combinations and values of the indicators 
should converge toward relatively stable configurations that will allow informed 
judgment of capacity for program management.  
 
The profiles would combine various possibilities for the indicators in the two areas. For 
example, teams of industry-university collaborators with more technological 
development experience and patent holding on the industry side and higher credentials 
and experience with sophisticated testing equipment on the university side and a 
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pattern of use of each others’ facilities might be a typical joint venture profile. More 
interestingly, profiles that defy stereotypes such as these may certainly emerge from the 
data making the role of KISTEP all the more constructive in facilitating the evolution of 
the HT field.   
 
Various tools and modeling approaches in data analysis can be used for this purpose. 
For example, using network models of collaboration based on publications, joint venture 
information, patents with multiple assignees, and other such indicators and observing 
their dynamic evolution can provide valuable insights on the positioning of these actors 
in the HT field. Similar approaches can be used to track career trajectories of team 
members and their location when participating in relevant past projects. The evolution of 
their career in the aftermath of such projects may reveal rewards or less than favorable 
response to their results that are not directly reported in CVs and other information 
sources.  
 
The limited scope of this project has not allowed the gathering of test data to illustrate 
these points. However, it should not be too difficult to envision. 
 
 
IV. Data Structures for Health Technology Development Capacity 
The data requirements for the capacity assessment function proposed in this project 
have several dimensions. Capacity assessment of potential candidates for the 
execution of technology projects requires the development of in-house capacity to 
understand the fields of technology in which the agency has strategic interest. The 
foundation of this capacity is a continuous effort in data development about those fields 
of technology activity. The data components recommended below are meant to be 
monitored continuously to build what essentially amounts to an observatory of the field 
of interest. The adjudication of capacity assessment in a one-time snapshot is 
essentially impossible. The ability to make these judgments will essentially be based on 
the capacity of the agency to learn from continuous observation of the field of interest 
11 
 





 Research journals 





CV analysis presents some challenges (Dietz et al. 2000). There is no uniform format 
for CVs so there is no guarantee that they will contain all the information that is needed 
for the indicators. There is a marked difference between CVs in the academic sector 
and those usually used in the private sector. The former are more detailed and 
generally contain a fairly complete record of former academic appointments and 
publications. The latter are generally much shorter and contain the most recent 
information relevant to the current position. Therefore, the construction of a database of 
CVs is quite laborious and no useful automatic harvesting of CVs is available to date.   
 
From the indicator definitions in the previous section it is clear that at least the following 
fields from CVs must be included: 
 
Full Name 
Demographic information (Gender, Date of birth, Nationality) 
Education information (Degrees, Dates, Institutions, Fields) 
Employment information (past and present) 
Publication information (full reference) 
Patent information (title, granted status, dates of application and grant, field codes, 
awardees’ affiliation data) 




The publication and patent information can be triangulated for data cleaning purposes 
with data from the data infrastructure sources such as Web of Science and Scopus for 
publications and the patent offices’ data for patents.  
 
The publication and patents database components must rest on a search strategy that 
identifies the field of HT clearly. The boundaries of the field of interest will be 
determined by the search strategy that is used to gather all the publications and patents 
in a relevant period. At the beginning of the effort to apply these recommendations, the 
deliberation based on the strategic focus of KISTEP must be conducted to arrive at the 
definition of the HT field and its corresponding set of search terms for use in the general 
databases. An example of such a strategy for the field of nanotechnology is shown in 
Porter and Youtie (2008). A stable definition of the field based on a search strategy will 
enable orderly continuous updating of the databases in order to maintain the capacity to 
build the latest profiles of the organizations and personnel of interest. 
 
The information on firms can be developed from public or proprietary databases of 
firms, which must be verified for availability in Korea, and from firm websites. For a 
focus field such as the HT area, it is advisable to conduct periodic surveys of firms 
(every 3-4 years). The information on firms would include at least the following fields: 
 
Name of the firm 
Date of foundation 
Ownership information 
Size (employees and sales) 
Product line 
Intellectual property (from patent databases and disclosure) 
R&D activity (budget, facilities, number of R&D personnel) 
 
This information will be an important resource for many decisions in the process of 
interpreting data contained in the CVs and the claims made in HT project proposals in 
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terms of the relevance, technical quality and innovativeness of its substance. Therefore 
we recommend that for any serious effort of capacity assessment in a field of interest, 
especially in technology projects, the development of general data resources such as 
these that give the agency critical expertise on the shape of the fields in which the 
projects will be carried out. This will enable true evidence-based program management.   
 
V. Summary of Recommendations 
 
To conclude, we present a summary list of the recommendations explained in the body 
of this report: 
 
1. For the HT Capacity Assessment:  
a. Develop a data base that is regularly updated in time 
b. Main items in the data base are 
i. Qualified personnel in the country 
ii. Candidate organizations to perform HT projects 
c. Develop an indicator structure as shown in Table 1 
d. Develop profiles of HT performers in the country and update annually  
e. Data sources are: 
i. CV 
ii. Publication data bases 
iii. Patent data bases 
iv. Firm and product databases 
v. Firm and R&D organization websites 
vi. Surveys of HT organizations 
2. HT review and evaluation process: 
a. Implement Technology Opportunities Analysis in HT 
b. Implement HT project monitoring and ex-post follow up (using ATP model) 
 
The full set of recommendations amounts to an HT observatory operation for facilitation 
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Figure 1: Model of Health Technology Capacity Assessment Framework 
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